JP2021521851A5 - - Google Patents

Info

Publication number
JP2021521851A5
JP2021521851A5 JP2020560355A JP2020560355A JP2021521851A5 JP 2021521851 A5 JP2021521851 A5 JP 2021521851A5 JP 2020560355 A JP2020560355 A JP 2020560355A JP 2020560355 A JP2020560355 A JP 2020560355A JP 2021521851 A5 JP2021521851 A5 JP 2021521851A5
Authority
JP
Japan
Prior art keywords
gene therapy
therapy vector
vector according
disease
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020560355A
Other languages
English (en)
Japanese (ja)
Other versions
JP7749322B2 (ja
JP2021521851A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/030076 external-priority patent/WO2019213180A1/en
Publication of JP2021521851A publication Critical patent/JP2021521851A/ja
Publication of JP2021521851A5 publication Critical patent/JP2021521851A5/ja
Priority to JP2024068431A priority Critical patent/JP2024119788A/ja
Application granted granted Critical
Publication of JP7749322B2 publication Critical patent/JP7749322B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020560355A 2018-04-30 2019-04-30 遺伝子治療構築物及び使用方法 Active JP7749322B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024068431A JP2024119788A (ja) 2018-04-30 2024-04-19 遺伝子治療構築物及び使用方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862664741P 2018-04-30 2018-04-30
US62/664,741 2018-04-30
US201862688640P 2018-06-22 2018-06-22
US62/688,640 2018-06-22
US201862744068P 2018-10-10 2018-10-10
US62/744,068 2018-10-10
PCT/US2019/030076 WO2019213180A1 (en) 2018-04-30 2019-04-30 Gene therapy constructs and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024068431A Division JP2024119788A (ja) 2018-04-30 2024-04-19 遺伝子治療構築物及び使用方法

Publications (3)

Publication Number Publication Date
JP2021521851A JP2021521851A (ja) 2021-08-30
JP2021521851A5 true JP2021521851A5 (cg-RX-API-DMAC7.html) 2022-05-11
JP7749322B2 JP7749322B2 (ja) 2025-10-06

Family

ID=66669057

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020560355A Active JP7749322B2 (ja) 2018-04-30 2019-04-30 遺伝子治療構築物及び使用方法
JP2024068431A Withdrawn JP2024119788A (ja) 2018-04-30 2024-04-19 遺伝子治療構築物及び使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024068431A Withdrawn JP2024119788A (ja) 2018-04-30 2024-04-19 遺伝子治療構築物及び使用方法

Country Status (16)

Country Link
US (3) US10874750B2 (cg-RX-API-DMAC7.html)
EP (1) EP3788064A1 (cg-RX-API-DMAC7.html)
JP (2) JP7749322B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210005154A (cg-RX-API-DMAC7.html)
CN (1) CN112513071A (cg-RX-API-DMAC7.html)
AU (1) AU2019261982A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020021962A2 (cg-RX-API-DMAC7.html)
CA (1) CA3098674A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020002809A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020014729A2 (cg-RX-API-DMAC7.html)
MX (1) MX2020011514A (cg-RX-API-DMAC7.html)
PH (1) PH12020551818A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202010533WA (cg-RX-API-DMAC7.html)
TW (2) TW202344691A (cg-RX-API-DMAC7.html)
WO (1) WO2019213180A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202006905B (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202344691A (zh) * 2018-04-30 2023-11-16 美商阿米庫斯醫療股份有限公司 基因治療構築體及使用方法
JP7577650B2 (ja) 2018-10-10 2024-11-05 アミカス セラピューティックス インコーポレイテッド ジスルフィド結合により安定したポリペプチド組成物及びその使用方法
JP2022552254A (ja) * 2019-10-10 2022-12-15 アミカス セラピューティックス インコーポレイテッド バリアントigf2構築体
WO2021102107A1 (en) * 2019-11-19 2021-05-27 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus comprising liver-specific promoters for treating pompe disease and lysosomal disorders
EP4081241A4 (en) 2019-12-24 2024-05-01 Juvena Therapeutics, Inc. REGENERATIVE POLYPEPTIDES AND USES THEREOF
JP7443761B2 (ja) 2019-12-25 2024-03-06 東洋紡エムシー株式会社 中空糸膜モジュール
EP4149519A4 (en) * 2020-05-14 2024-06-12 The Trustees of The University of Pennsylvania COMPOSITIONS FOR THE TREATMENT OF POMPE DISEASE
BR112023001456A2 (pt) 2020-07-27 2023-04-11 Voyager Therapeutics Inc Composições e métodos para o tratamento de distúrbios neurológicos relacionados à deficiência de beta glicosilceramidase
US20230285596A1 (en) 2020-07-27 2023-09-14 Voyager Therapeutics, Inc Compositions and methods for the treatment of niemann-pick type c1 disease
CN111733174B (zh) * 2020-08-07 2021-02-09 北京大学第三医院(北京大学第三临床医学院) 一种分离的核酸分子及其用途
WO2022081794A1 (en) * 2020-10-15 2022-04-21 Tavotek Biotherapeutics (Hong Kong) Limited Shielded biologics with masking domains to shield antigen binding capability of biologics and uses thereof
US20220153869A1 (en) * 2020-11-16 2022-05-19 Tavotek Biotherapeutics (Hong Kong) Limited Shielded and homing bispecific antibody that simultaneously inhibits angiogenic pathway targets and her2 family proteins and uses thereof
WO2022119890A1 (en) 2020-12-01 2022-06-09 The Trustees Of The University Of Pennsylvania Compositions and uses thereof for treatment of angelman syndrome
EP4359425B1 (en) 2021-06-21 2026-08-05 Juvena Therapeutics, Inc. Igf2 fusion polypeptide and use in the treatment of muscular dystrophy, sarcopenia, cachexia, or muscle injury
US20250034533A1 (en) * 2021-11-12 2025-01-30 Amicus Therapeutics, Inc. Compositions And Methods For Treating Mucopolysaccharidosis IIIA
US20250049955A1 (en) 2021-11-17 2025-02-13 Voyager Therapeutics, Inc. Compositons and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
WO2023240236A1 (en) 2022-06-10 2023-12-14 Voyager Therapeutics, Inc. Compositions and methods for the treatment of spinal muscular atrophy related disorders
US20260216373A1 (en) 2023-01-13 2026-07-30 Amicus Therapeutics, Inc. Gene Therapy Constructs for the Treatment of Pompe Disease
AU2023427408A1 (en) 2023-02-02 2025-09-04 Voyager Therapeutics, Inc. Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
WO2024226761A2 (en) 2023-04-26 2024-10-31 Voyager Therapeutics, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
WO2026006281A1 (en) * 2024-06-24 2026-01-02 Remedium Bio, Inc. A system for delivering genetic material subcutaneously with elements enabling subsequent post-treatment identification, localization, quantification, evaluation, or targeting for up- and/or down-titration

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087164A (en) * 1997-10-03 2000-07-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
EP1118334A1 (en) 2000-01-11 2001-07-25 Aventis Behring Gesellschaft mit beschränkter Haftung Method for the production of conjugates and uses thereof for the prevention and treatment of allergic reactions and autoimmune diseases
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
EP1436316B1 (en) 2001-04-30 2008-01-23 ZyStor Therapeutics , Inc. Subcellular targeting of therapeutic proteins
WO2003032913A2 (en) * 2001-10-16 2003-04-24 Symbiontics Inc. Methods and compositions for targeting proteins across the blood brain barrier
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
DE10237639A1 (de) * 2002-08-13 2004-02-26 Martin-Luther-Universität Halle-Wittenberg Verfahren zur Herstellung von virusanalogen Partikeln durch in vitro-Assemblierung von Kapsomeren oder von Kapsomeren, an die biologisch aktive Makromoleküle gebunden sind, bei gleichzeitiger Verpackung der Makromoleküle
PT1587923E (pt) 2003-01-22 2011-12-07 Univ Duke Construções melhoradas para a expressão de polipéptidos lisossomais
JP4979067B2 (ja) * 2003-05-01 2012-07-18 ジェンザイム・コーポレーション 神経代謝性疾患についての遺伝子治療
GB0314856D0 (en) 2003-06-25 2003-07-30 Unitargeting Res As Protein expression system
US7355018B2 (en) 2003-09-30 2008-04-08 Regeneron Pharmaceuticals, Inc. Modified IGF1 polypeptides with increased stability and potency
DE602005020745D1 (de) 2004-02-10 2010-06-02 Zystor Therapeutics Inc Saure alpha-glukosidase und fragmente davon
ES2242542B1 (es) * 2004-04-30 2006-12-16 Consejo Superior De Investigaciones Cientificas Procedimiento para la produccion en levaduras de capsidas virales vacias compuestas por proteinas derivadas de pvp2 del virus causante de la enfermedad de la bursitis infecciosa (ibdv).
WO2006007560A2 (en) 2004-07-01 2006-01-19 University Of Pennsylvania Targeted protein replacement for the treatment of lysosomal storage disorders
CN1903374A (zh) * 2005-07-27 2007-01-31 中国人民解放军军事医学科学院生物医学分析中心 大肠杆菌在制备肿瘤诊断或治疗药物中的用途
AU2007322123A1 (en) 2006-11-13 2008-05-29 Biomarin Pharmaceutical Inc. Methods for treating Pompe disease
WO2009137721A2 (en) 2008-05-07 2009-11-12 Zystor Therapeutics, Inc. Lysosomal targeting peptides and uses thereof
PL3912643T3 (pl) 2009-02-13 2023-01-23 Immunomedics Inc. Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo
HRP20181315T1 (hr) 2010-11-22 2018-10-19 Amicus Therapeutics, Inc. Nove signalne sekvence za poboljšanje ekspresije proteina i izlučivanja rekombinantnih enzima i drugih proteina
US9662375B2 (en) * 2010-11-30 2017-05-30 Orphazyme Aps Methods for increasing intracellular activity of Hsp70
US8580922B2 (en) 2011-03-04 2013-11-12 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same
EP2687597B1 (en) 2011-03-16 2018-12-26 Amano Enzyme Inc. Modified alpha-glucosidase and applications of same
LT2714752T (lt) 2011-05-27 2018-03-12 Amicus Therapeutics, Inc. Nukreipiančių peptidų kopuliavimo ant rekombinantinių lizosominių fermentų būdai, skirti lizosominio kaupimo ligų gydymo pagerinimui
US9387236B2 (en) * 2011-06-10 2016-07-12 Prothera Inc. Pharmaceutical compositions containing protease and methods for the treatment of lysosomal storage diseases
ES2679374T3 (es) * 2012-11-27 2018-08-24 Biomarin Pharmaceutical Inc. Proteínas de fusión terapéuticas dirigidas de enzima lisosómica y usos de las mismas
EP2976092B1 (en) * 2013-03-15 2020-04-22 Amicus Therapeutics, Inc. Chemical crosslinkers
WO2015060722A1 (en) * 2013-10-24 2015-04-30 Uniqure Ip B.V. Aav-5 pseudotyped vector for gene therapy for neurological diseases
WO2015085238A1 (en) 2013-12-05 2015-06-11 The Regents Of The University Of California, A California Corporation Inhibitors of lpxc
TW202344691A (zh) * 2018-04-30 2023-11-16 美商阿米庫斯醫療股份有限公司 基因治療構築體及使用方法
JP2022552254A (ja) * 2019-10-10 2022-12-15 アミカス セラピューティックス インコーポレイテッド バリアントigf2構築体

Similar Documents

Publication Publication Date Title
US10202591B2 (en) Methods and compositions for treatment of glycogen storage diseases and glycogen metabolism disorders
IL273439B2 (en) Fusion proteins involving enzyme replacement in enzyme therapy
JP2022512689A5 (cg-RX-API-DMAC7.html)
KR20210005154A (ko) 유전자 요법 작제물 및 사용 방법
AU2003215869B2 (en) Hybrid and single chain meganucleases and use thereof
WO2014130722A1 (en) Methods and compositions for treatment of forbes-cori disease
IL276464B1 (en) Methods and compositions for administering therapeutic protein
JP2021512899A5 (cg-RX-API-DMAC7.html)
JP2022519507A5 (cg-RX-API-DMAC7.html)
JP2022552254A5 (cg-RX-API-DMAC7.html)
KR20250021616A (ko) 신규 히알루론산 가수분해 효소 변이체 및 이를 포함하는 약제학적 조성물
JP2021507705A (ja) 新規な構造を有する治療学的酵素融合タンパク質及びその用途
JP2022552254A (ja) バリアントigf2構築体
JP2007525997A (ja) アドザイムおよびその使用法
JP2005537032A (ja) アドザイムおよびその用途
WO2015009052A1 (ko) 하이브리드 면역글로불린 fc와 효소의 융합단백질
KR20150132126A (ko) 화학적 가교결합제
Yoon et al. Cloning and cytotoxicity of fusion proteins of EGF and angiogenin
Das et al. Multifunctional activities of human fibroblast 34-kDa hyaluronic acid-binding protein
US20080025995A1 (en) Cross-Placenta Delivery System
AU2023210789A1 (en) Iga protease truncation, fusion protein comprising iga protease truncation, and use thereof
CA2529553A1 (en) Ribonucleases and methods of making them recombinantly
US20240318157A1 (en) Neurotensin Variants And Tagged Proteins Comprising Neurotensin Or Sortilin Propeptide
KR101582655B1 (ko) 광활성 메티오닌 모사체 표지 단백질 생합성을 위한 메티오닐 tRNA 합성효소 변이체
WO2025264978A3 (en) Recombinant alpha-galactosidase a proteins and gene therapy